{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:47:38Z","timestamp":1793119658474,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40121-024-01086-y","type":"journal-article","created":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T15:57:39Z","timestamp":1732982259000},"page":"133-148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Acute Infusion-Related Side Effects of Amphotericin\u00a0B Lipid Complex (ABLC) in Oncohematological Patients: Real-World Data from Brazilian Reference Centers"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7295-0828","authenticated-orcid":false,"given":"Francelise","family":"Bridi Cavassin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello Mihailenko Chaves","family":"Magri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariela Victoria","family":"Borgmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela Dombeck","family":"Floriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Rachid","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Zaleski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabianne Altruda","family":"de Moraes Costa Carlesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Lu\u00eds","family":"Breda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1bio","family":"de Ara\u00fajo Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego Rodrigues","family":"Falci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Verena Almeida","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo Paz","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia Silva","family":"Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariane","family":"Taborda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talita Teles Teixeira","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Luiz","family":"Ba\u00fa-Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fl\u00e1vio","family":"Queiroz-Telles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,30]]},"reference":[{"issue":"4","key":"1086_CR1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3390\/jof6040281","volume":"6","author":"J-P Gangneux","year":"2020","unstructured":"Gangneux J-P, Padoin C, Michallet M, et al. Outcomes of antifungal prophylaxis in high-risk haematological patients (AML under intensive chemotherapy): the SAPHIR prospective multicentre study. J Fungi. 2020;6(4):281.","journal-title":"J Fungi"},{"issue":"100","key":"1086_CR2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"2004","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia. Cancer. 2004;2004(100):228\u201337.","journal-title":"Cancer"},{"issue":"6","key":"1086_CR3","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1634\/theoncologist.2008-0012","volume":"13","author":"CH Chung","year":"2008","unstructured":"Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008;13(6):725\u201332.","journal-title":"Oncologist"},{"issue":"2","key":"1086_CR4","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1188\/10.CJON.E10-E21","volume":"14","author":"WH Vogel","year":"2010","unstructured":"Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs. 2010;14(2):E10-21.","journal-title":"Clin J Oncol Nurs"},{"issue":"5","key":"1086_CR5","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1592\/phco.25.5.690.63591","volume":"25","author":"PN Malani","year":"2005","unstructured":"Malani PN, DePestel DD, Riddell J, Bickley S, Klein LR, Kauffman CA. Experience with community-based amphotericin\u00a0B infusion therapy. Pharmacotherapy. 2005;25(5):690\u20137.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"1086_CR6","doi-asserted-by":"crossref","first-page":"340","DOI":"10.7326\/0003-4819-61-2-340","volume":"61","author":"JP Utz","year":"1964","unstructured":"Utz JP. General side effects. Ann Intern Med. 1964;61(2):340.","journal-title":"Ann Intern Med"},{"issue":"2","key":"1086_CR7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1681\/ASN.V62154","volume":"6","author":"BP Sawaya","year":"1995","unstructured":"Sawaya BP, Briggs JP, Schnermann J. Amphotericin\u00a0B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol. 1995;6(2):154\u201364.","journal-title":"J Am Soc Nephrol"},{"key":"1086_CR8","first-page":"343","volume-title":"Advances in pharmacology","author":"AH Groll","year":"1998","unstructured":"Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. In: Advances in pharmacology. Amsterdam: Elsevier; 1998. p. 343\u2013500."},{"issue":"1","key":"1086_CR9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40121-020-00382-7","volume":"10","author":"FB Cavassin","year":"2021","unstructured":"Cavassin FB, Ba\u00fa-Carneiro JL, Vilas-Boas RR, Queiroz-Telles F. Sixty years of amphotericin\u00a0B: an overview of the main antifungal agent used to treat invasive fungal infections. Infect Dis Ther. 2021;10(1):115\u201347.","journal-title":"Infect Dis Ther"},{"issue":"6","key":"1086_CR10","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/516353","volume":"26","author":"TJ Walsh","year":"1998","unstructured":"Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin\u00a0B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998;26(6):1383\u201396.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"1086_CR11","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.bmt.1702243","volume":"25","author":"GJ Timmers","year":"2000","unstructured":"Timmers GJ, Zweegman S, Simoons-Smit AM, van Loenen AC, Touw D, Huijgens PC. Amphotericin\u00a0B colloidal dispersion (amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. Bone Marrow Transplant. 2000;25(8):879\u201384.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"1086_CR12","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/clinids\/20.4.755","volume":"20","author":"SD Goodwin","year":"1995","unstructured":"Goodwin SD, Cleary JD, Walawander CA, Taylor JW, Grasela TH. Pretreatment regimens for adverse events related to infusion of amphotericin\u00a0B. Clin Infect Dis. 1995;20(4):755\u201361.","journal-title":"Clin Infect Dis"},{"key":"1086_CR13","unstructured":"B.V TPE. Package leaflet: information for the user\u2014Abelcet\u00ae Lipid Complex 5\u00a0mg\/ml concentrate for dispersion for infusion. In: Pharmaceuticals T, editor. Netherlands; 2020."},{"key":"1086_CR14","unstructured":"Dutcher JD GW, Pagano JF, Vandeputte J. Amphotericin\u00a0B, its production, and its salts. In: Office USP, editor. United States Patent Office; 1959."},{"key":"1086_CR15","unstructured":"US AP. AmBisome. In: US AP, editor. Northbrook, IL; 2023."},{"issue":"12","key":"1086_CR16","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B De Pauw","year":"2008","unstructured":"De Pauw B, Walsh Thomas J, Peter DJ, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813\u201321.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1086_CR17","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2019","unstructured":"Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2019;71(6):1367\u201376.","journal-title":"Clin Infect Dis"},{"issue":"11\u201312","key":"1086_CR18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1439-0507.1995.tb00020.x","volume":"38","author":"M Arning","year":"1995","unstructured":"Arning M, Kliche KO, Heer-Sonderhoff AH, Wehmeier A. Infusion-related toxicity of three different amphotericin\u00a0B formulations and its relation to cytokine plasma levels. Mycoses. 1995;38(11\u201312):459\u201365.","journal-title":"Mycoses"},{"issue":"9","key":"1086_CR19","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","volume":"73","author":"RJ Hamill","year":"2013","unstructured":"Hamill RJ, Amphotericin\u00a0B. Formulations: a comparative review of efficacy and toxicity. Drugs. 2013;73(9):919\u201334.","journal-title":"Drugs"},{"issue":"2","key":"1086_CR20","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/jac\/dkh542","volume":"55","author":"S Bellocchio","year":"2005","unstructured":"Bellocchio S, Gaziano R, Bozza S, et al. Liposomal amphotericin\u00a0B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. J Antimicrob Chemother. 2005;55(2):214\u201322.","journal-title":"J Antimicrob Chemother"},{"key":"1086_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2012.00286","author":"AC Mesa-Arango","year":"2012","unstructured":"Mesa-Arango AC, Scorzoni L, Zaragoza O. It only takes one to do many jobs: amphotericin\u00a0B as antifungal and immunomodulatory drug. Front Microbiol. 2012. https:\/\/doi.org\/10.3389\/fmicb.2012.00286.","journal-title":"Front Microbiol"},{"issue":"3","key":"1086_CR22","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1128\/AAC.45.3.679-685.2001","volume":"45","author":"DE Varlam","year":"2001","unstructured":"Varlam DE, Siddiq MM, Parton LA, R\u00fcssmann H. Apoptosis contributes to amphotericin\u00a0B-induced nephrotoxicity. Antimicrob Agents Chemother. 2001;45(3):679\u201385.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1086_CR23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/sj.bmt.1700664","volume":"19","author":"J Wingard","year":"1997","unstructured":"Wingard J. Efficacy of amphotericin\u00a0B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant. 1997;19(4):343\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"1086_CR24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/cid\/ciw444","volume":"63","author":"T Patterson","year":"2016","unstructured":"Patterson T, Thompson G 3rd, Denning D, et al. Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63:433\u201342.","journal-title":"Clin Infect Dis"},{"key":"1086_CR25","unstructured":"Amphotericin\u00a0B lipid complex (ABLC) | Johns Hopkins ABX guide. www.hopkinsguides.com. https:\/\/www.hopkinsguides.com\/hopkins\/view\/Johns_Hopkins_ABX_Guide\/540021\/all\/Amphotericin_B_lipid_complex__ABLC_. Accessed 2022 Jun 24."},{"key":"1086_CR26","unstructured":"Chen SC-A, Perfect J, Colombo AL, et al. Global guideline for the diagnosis and management of invasive infections caused by emerging, uncommon or rare yeasts. 2020. https:\/\/www.clinicalsurveys.net\/uc\/admin\/5445\/images\/Rare_Yeasts_Guideline_Draft_Public_Consultation.pdf.  Accessed 2020 Oct 5."},{"issue":"5\u20136","key":"1086_CR27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/10428190109097650","volume":"40","author":"RV Fleming","year":"2001","unstructured":"Fleming RV, Kantarjian HM, Husni R, et al. Comparison of amphotericin\u00a0B lipid complex (ABLC) vs. am bisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leukemia Lymphoma. 2001;40(5\u20136):511\u201320.","journal-title":"Leukemia Lymphoma"},{"key":"1086_CR28","volume-title":"The Harriet Lane handbook: the Johns Hopkins Hospital","author":"K Kleinman","year":"2020","unstructured":"Kleinman K, Mcdaniel L, Molloy M. The Harriet Lane handbook: the Johns Hopkins Hospital. 22nd ed. Amsterdam: IDSA, Elsevier; 2020.","edition":"22"},{"key":"1086_CR29","doi-asserted-by":"crossref","first-page":"102366","DOI":"10.1016\/j.nano.2021.102366","volume":"34","author":"G Milosevits","year":"2021","unstructured":"Milosevits G, M\u00e9sz\u00e1ros T, \u0150rfi E, et al. Complement-mediated hypersensitivity reactions to an amphotericin\u00a0B-containing lipid complex (Abelcet) in pediatric patients and anesthetized rats: benefits of slow infusion. Nanomed Nanotechnol Biol Med. 2021;34:102366.","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"10","key":"1086_CR30","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.clinthera.2021.09.011","volume":"43","author":"T Scardina","year":"2021","unstructured":"Scardina T, Fawcett AJ, Patel SJ. Amphotericin-associated infusion-related reactions: a narrative review of pre-medications. Clin Ther. 2021;43(10):1689\u2013704.","journal-title":"Clin Ther"},{"key":"1086_CR31","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1007\/s12070-021-02838-9","volume":"74","author":"K Sachdeva","year":"2021","unstructured":"Sachdeva K, Saji TA. Adverse drug reaction of antifungals in the management of black fungus: a tertiary care centre experience. Indian J Otolaryngol Head Neck Surg. 2021;74:3111\u20137.","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"key":"1086_CR32","first-page":"2","volume":"5","author":"R Moghnieh","year":"2016","unstructured":"Moghnieh R, El-Rajab N, Abdallah DI, et al. Retrospective analysis on the use of amphotericin\u00a0B lipid complex in neutropenic cancer patients with suspected fungal infections in Lebanon, a single center experience and review of international guidelines. Front Med. 2016;5:2.","journal-title":"Front Med"},{"issue":"5","key":"1086_CR33","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/cid\/cis972","volume":"56","author":"D Farmakiotis","year":"2012","unstructured":"Farmakiotis D, Tverdek FP, Kontoyiannis DP. The safety of amphotericin\u00a0B lipid complex in patients with prior severe intolerance to liposomal amphotericin\u00a0B. Clin Infect Dis. 2012;56(5):701\u20133.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1086_CR34","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1185\/03007990902752753","volume":"25","author":"N O\u2019Connor","year":"2009","unstructured":"O\u2019Connor N, Borley A. Prospective audit of the effectiveness of hydrocortisone premedication on drug delivery reactions following amphotericin\u00a0B lipid complex. Curr Med Res Opin. 2009;25(3):749\u201354.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"1086_CR35","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1600-0609.2004.00239.x","volume":"72","author":"M Subir\u00e0","year":"2004","unstructured":"Subir\u00e0 M, Martino R, G\u00f3mez L, Mart\u00ed JM, Estany C, Sierra J. Low-dose amphotericin b lipid complex vs. conventional amphotericin\u00a0B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies\u2014a randomized, controlled trial. Eur J Haematol. 2004;72(5):342\u20137.","journal-title":"Eur J Haematol"},{"issue":"3","key":"1086_CR36","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/sj.bmt.1702156","volume":"25","author":"M Furebring","year":"2000","unstructured":"Furebring M, \u00d6berg G, Sj\u00f6lin J. Side-effects of amphotericin\u00a0B lipid complex (Abelcet) in the Scandinavian population. Bone Marrow Transplant. 2000;25(3):341\u20132.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"1086_CR37","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","volume":"31","author":"JR Wingard","year":"2000","unstructured":"Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin\u00a0B versus amphotericin\u00a0B lipid complex in the empirical treatment of febrile neutropenia. L Amph\/ABLC Collaborative Study Group. Clin Infect Dis. 2000;31(5):1155\u201363.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"1086_CR38","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1198-743X.2004.00963.x","volume":"10","author":"J-M Aguado","year":"2004","unstructured":"Aguado J-M, Lumbreras C, Gonz\u00e1lez-Vidal D. Assessment of nephrotoxicity in patients receiving amphotericin\u00a0B lipid complex: a pharmacosurveillance study in Spain. Clin Microbiol Infect. 2004;10(9):785\u201390.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"1086_CR39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1517\/14740330903418430","volume":"9","author":"C Craddock","year":"2010","unstructured":"Craddock C, Anson J, Chu P, et al. Best practice guidelines for the management of adverse events associated with amphotericin\u00a0B lipid complex. Expert Opin Drug Saf. 2010;9(1):139\u201347.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"1086_CR40","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000219534","volume":"3","author":"JH Seabury","year":"1961","unstructured":"Seabury JH. Experience with amphotericin\u00a0B. Chemotherapy. 1961;3(2):81\u201394.","journal-title":"Chemotherapy"},{"issue":"2","key":"1086_CR41","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1378\/chest.41.2.214","volume":"41","author":"A Saliba","year":"1962","unstructured":"Saliba A, Beatty OA. Treatment of mycotic infections: hydrocortisone in the control of amphotericin-B toxicity. Dis Chest. 1962;41(2):214\u20139.","journal-title":"Dis Chest"},{"issue":"5","key":"1086_CR42","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/infdis\/156.5.784","volume":"156","author":"F Gigliotti","year":"1987","unstructured":"Gigliotti F, Shenep JL, Lott L, Thornton D. Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin\u00a0B. J Infect Dis. 1987;156(5):784\u20139.","journal-title":"J Infect Dis"},{"key":"1086_CR43","first-page":"541","volume-title":"Side effects of drugs annual","author":"D Schrey","year":"2011","unstructured":"Schrey D, Walsh TJ, Groll AH. Antifungal drugs. In: Side effects of drugs annual. Amsterdam: Elsevier; 2011. p. 541\u201366."},{"issue":"4","key":"1086_CR44","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/archinte.1980.00330160043024","volume":"140","author":"LC Burks","year":"1980","unstructured":"Burks LC. Meperidine for the treatment of shaking chills and fever. Arch Intern Med. 1980;140(4):483\u20134.","journal-title":"Arch Intern Med"},{"issue":"5","key":"1086_CR45","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1080\/23744235.2019.1568546","volume":"51","author":"DB Chastain","year":"2019","unstructured":"Chastain DB, Giles RL, Bland CM, Franco-Paredes C, Henao-Mart\u00ednez AF, Young HN. A clinical pharmacist survey of prophylactic strategies used to prevent adverse events of lipid-associated formulations of amphotericin\u00a0B. Infect Dis. 2019;51(5):380\u20133.","journal-title":"Infect Dis"},{"issue":"5","key":"1086_CR46","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/bcp.13521","volume":"84","author":"EC Andrew","year":"2018","unstructured":"Andrew EC, Curtis N, Coghlan B, Cranswick N, Gwee A. Adverse effects of amphotericin\u00a0B in children; a retrospective comparison of conventional and liposomal formulations. Br J Clin Pharmacol. 2018;84(5):1006\u201312.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"1086_CR47","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1086\/374553","volume":"36","author":"MM Roden","year":"2003","unstructured":"Roden MM, Nelson LD, Knudsen TA, et al. Triad of acute infusion-related reactions associated with liposomal amphotericin\u00a0B: analysis of clinical and epidemiological characteristics. Clin Infect Dis. 2003;36(10):1213\u201320.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1086_CR48","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.diagmicrobio.2013.04.001","volume":"76","author":"RL Wade","year":"2013","unstructured":"Wade RL, Chaudhari P, Natoli JL, Taylor RJ, Nathanson BH, Horn DL. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin\u00a0B or amphotericin\u00a0B lipid complex. Diagn Microbiol Infect Dis. 2013;76(3):361\u20137.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"1086_CR49","doi-asserted-by":"crossref","first-page":"H1319","DOI":"10.1152\/ajpheart.2000.279.3.H1319","volume":"279","author":"J Szebeni","year":"2000","unstructured":"Szebeni J, Baranyi L, Savay S, et al. Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. Am J Physiol Heart Circ Physiol. 2000;279(3):H1319\u201328.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"1086_CR50","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.clinthera.2024.01.011","volume":"46","author":"FB Cavassin","year":"2024","unstructured":"Cavassin FB, Magri MMC, Vidal JE, et al. Effectiveness, tolerability, and safety of different amphotericin b formulations in invasive fungal infections: a multicenter, retrospective, observational study. Clin Ther. 2024;46(4):322\u201337. https:\/\/doi.org\/10.1016\/j.clinthera.2024.01.011.","journal-title":"Clin Ther"},{"issue":"2","key":"1086_CR51","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/ajh.2830310206","volume":"31","author":"JP Dutcher","year":"1989","unstructured":"Dutcher JP, Kendall J, Norris D, Schiffer C, Aisner J, Wiernik PH. Granulocyte transfusion therapy and amphotericin\u00a0B: adverse reactions? Am J Hematol. 1989;31(2):102\u20138. https:\/\/doi.org\/10.1002\/ajh.2830310206.","journal-title":"Am J Hematol"},{"issue":"1","key":"1086_CR52","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/blood.V57.1.90.90","volume":"57","author":"BW Dana","year":"1981","unstructured":"Dana BW, Durie BG, White RF, Huestis DW. Concomitant administration of granulocyte transfusions and amphotericin\u00a0B in neutropenic patients: absence of significant pulmonary toxicity. Blood. 1981;57(1):90\u20134.","journal-title":"Blood"},{"issue":"4","key":"1086_CR53","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1093\/clind\/16.4.528","volume":"16","author":"RT Spielberger","year":"1993","unstructured":"Spielberger RT, Falleroni MJ, Coene AJ, Larson RA. Concomitant amphotericin\u00a0B therapy, granulocyte transfusions, and GM-CSF administration for disseminated infection with Fusarium in a granulocytopenic patient. Clin Infect Dis. 1993;16(4):528\u201330. https:\/\/doi.org\/10.1093\/clind\/16.4.528.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1086_CR54","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1\u201360. https:\/\/doi.org\/10.1093\/cid\/ciw326.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1086_CR55","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood.v99.1.384","volume":"99","author":"ML Sulis","year":"2002","unstructured":"Sulis ML, Van de Ven C, Henderson T, Anderson L, Cairo MS. Liposomal amphotericin\u00a0B (AmBisome) compared with amphotericin\u00a0B +\/- FMLP induces significantly less in vitro neutrophil aggregation with granulocyte-colony-stimulating factor\/dexamethasone-mobilized allogeneic donor neutrophils. Blood. 2002;99(1):384\u20136. https:\/\/doi.org\/10.1182\/blood.v99.1.384.","journal-title":"Blood"},{"issue":"11","key":"1086_CR56","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1046\/j.1537-2995.2002.00249.x","volume":"42","author":"K H\u00fcbel","year":"2002","unstructured":"H\u00fcbel K, Carter RA, Liles WC, et al. Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion. 2002;42(11):1414\u201321. https:\/\/doi.org\/10.1046\/j.1537-2995.2002.00249.x.","journal-title":"Transfusion"},{"issue":"11","key":"1086_CR57","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.jcyt.2017.08.012","volume":"19","author":"J Gea-Banacloche","year":"2017","unstructured":"Gea-Banacloche J. Granulocyte transfusions: a concise review for practitioners. Cytotherapy. 2017;19(11):1256\u201369. https:\/\/doi.org\/10.1016\/j.jcyt.2017.08.012.","journal-title":"Cytotherapy"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01086-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-024-01086-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01086-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T05:58:44Z","timestamp":1738216724000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-024-01086-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,30]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1086"],"URL":"https:\/\/doi.org\/10.1007\/s40121-024-01086-y","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,30]]},"assertion":[{"value":"3 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Francelise Bridi Cavassin, Marcello Mihailenko Chaves Magri, Ariela Victoria Borgmann, Isabela Dombeck Floriani, Marina Rachid Barreto, Tania Zaleski, Fabianne Altruda de Moraes Costa Carlesse, Giovanni Lu\u00eds Breda, F\u00e1bio de Ara\u00fajo Motta, Diego Rodrigues Falci, Ana Verena Almeida Mendes, Hugo Paz Morales, Patr\u00edcia Silva Montes, Mariane Taborda, Talita Teles Teixeira Pereira, Jo\u00e3o Lu\u00eds Ba\u00fa-Carneiro, Fl\u00e1vio Queiroz-Telles declare no conflicts of interest for this specific study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Consent to use the data was obtained in all centers. Approval was granted by the ethics committees of the seven participating centers, with the Complexo Hospital de Cl\u00ednicas of the Federal University of Paran\u00e1 (CHC\/UFPR) being the study\u2019s coordinating center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}